References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424. doi: 10.3322/caac.21492
- van der Zee RP, Richel O, de Vries HJC, Prins JM. The increasing incidence of anal cancer: can it be explained by trends in risk groups? Neth J Med 2013; 71: 401-11. PMID: 24127500
- Ouhoummane N, Steben M, Coutlée F, Vuong T, Forest P, Rodier C, et al. Squamous anal cancer: patient characteristics and HPV type distribution. Cancer Epidemiol 2013; 37: 807-12. doi: 10.1016/j.canep.2013.09.015
- Klas JV, Rothenberger DA, Wong WD, Madoff RD. Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. Cancer 1999; 85:1686-93. doi: 10.1002/(sici)1097-0142(19990415)85:8<;1686::aid-cncr7>3.0.co;2-7
- Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N Engl J Med 2000; 342: 792-800. doi: 10.1056/NEJM200003163421107
- Nigro ND, Vaitkevicius VK, Considine BJ. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974; 17: 354-6. doi: 10.1007/BF02586980
- Czito BG, Willett CG. Current management of anal canal cancer. Curr Oncol Rep 2009; 11: 186-92. doi: 10.1007/s11912-009-0027-1
- Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15: 2040-9. doi: 10.1200/JCO.1997.15.5.2040
- Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996; 14: 2527-39. doi: 10.1200/JCO.1996.14.9.2527
- Shridhar R, Shibata D, Chan E, Thomas CR. Anal cancer: current standards in care and recent changes in practice. CA Cancer J Clin 2015; 65: 139-62. doi: 10.3322/caac.21259
- Hagemans JAW, Blinde SE, Nuyttens JJ, Morshuis WG, Mureau MAM, Rothbarth J, et al. Salvage abdominoperineal resection for squamous cell anal cancer: a 30-year single-institution experience. Ann Surg Oncol 2018; 25: 1970-9. doi: 10.1245/s10434-018-6483-9
- Hagemans JAW. ASO Author reflections: salvage surgery for anal cancer. Ann Surg Oncol 2018; 25: 852-3. doi: 10.1245/s10434-018-7025-1
- Jakovljevic K, Malisic E, Cavic M, Krivokuca A, Dobricic J, Jankovic R. KRAS and BRAF mutations in Serbian patients with colorectal cancer. J BUON 2012; 17: 575-80. PMID: 23033302
- Cavic M, Krivokuca A, Boljevic I, Brotto K, Jovanovic K, Tanic M, et al. Pharmacogenetics in cancer therapy ̶ 8 years of experience at the Institute for Oncology and Radiology of Serbia. J BUON 2016; 21: 1287-95. PMID: 27837635
- Serup-Hansen E, Linnemann D, Høgdall E, Geertsen PF, Havsteen H. KRAS and BRAF mutations in anal carcinoma. APMIS 2015; 123: 53-9. doi: 10.1111/apm.12306
- Brotto K, Malisic E, Cavic M, Krivokuca A, Jankovic R. The usability of allele-specific PCR and reverse-hybridization assays for KRAS genotyping in serbian colorectal cancer patients. Dig Dis Sci 2013; 58: 998-1003. doi: 10.1007/s10620-012-2469-9
- Lim F, Glynne-Jones R, Lim F, Glynne-Jones R. Chemotherapy/chemoradiation in anal cancer: a systematic review. Cancer Treat Rev 2011; 37: 520-32. doi: 10.1016/j.ctrv.2011.02.003
- Peiffert D, Tournier-Rangeard L, Gérard J-P, Lemanski C, François E, Giovannini M, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 2012; 30: 1941-8. doi: 10.1200/JCO.2011.35.4837
- Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, et al. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum 2008; 51: 147-53. doi: 10.1007/s10350-007-9125-z
- Huang K, Haas-Kogan D, Weinberg V, Krieg R. Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. World J Gastroenterol 2007; 13: 895-900. doi: 10.3748/wjg.v13.i6.895
- Hannoun-Levi JM, Ortholan C, Resbeut M, Teissier E, Ronchin P, Cowen D, et al. High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study). Int J Radiat Oncol Biol Phys 2011; 80: 712-20. doi: 10.1016/j.ijrobp.2010.02.055
- O’Sullivan B, Brierley J, Byrd D, Bosman F, Kehoe S, Kossary C, et al. The TNM classification of malignant tumours-towards common understanding and reasonable expectations. Lancet Oncol 2017; 18: 849-51. doi: 10.1016/S1470-2045(17)30438-2
- Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55. PMID: 7165009
- Matzinger O, Roelofsen F, Mineur L, Koswig S, Van Der Steen-Banasik EM, Van Houtte P, et al. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). Eur J Cancer 2009; 45: 2782-91. doi: 10.1016/j.ejca.2009.06.020
- Landsberg T, Chavaudra J, Dobbs J, Hanks G, Johansson K-A, Möller T, et al. Report 50. J Int Comm Radiat Units Meas 2016; os26: NP-NP. doi: 10.1093/jicru/os26.1.Report50
- Landsberg T, Chavaudra J, Dobbs J, Gerard JP, Hanks G, Horiot JC, et al. Report 62. J Int Comm Radiat Units Meas 2016; os32: NP-NP. doi: 10.1093/jicru/os32.1.Report62
- US Department of Health and Human Services, National Institutes of Health National Cancer Institute 2017. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. [cited 2021 Mar 15]. Available at https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf
- Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer 2016; 62: 132-7. doi: 10.1016/j.ejca.2016.03.081
- Lino-Silva LS, Salcedo-Hernández RA, Ruiz-García EB, García-Pérez L, Herrera-Gómez Á. Pre-operative Neutrophils/Lymphocyte Ratio in rectal cancer patients with preoperative chemoradiotherapy. Med Arch (Sarajevo, Bosnia Herzegovina) 2016; 70: 256-60. doi: 10.5455/medarh.2016.70.256-260
- Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol 2014; 111: 330-9. doi: 10.1016/j.radonc.2014.04.013
- Ortholan C, Ramaioli A, Peiffert D, Lusinchi A, Romestaing P, Chauveinc L, et al. Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. Int J Radiat Oncol Biol Phys 2005; 62: 479-85. doi: 10.1016/j.ijrobp.2004.09.060
- John M, Pajak T, Flam M, Hoffman J, Markoe A, Wolkov H, et al. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. Cancer J Sci Am 1996; 2: 20511. PMID: 9166533
- Pepek JM, Willett CG, Czito BG. Radiation therapy advances for treatment of anal cancer. J Natl Compr Canc Netw 2010; 8: 123-9. doi: 10.6004/jnccn.2010.0008
- Mitchell MP, Abboud M, Eng C, Beddar AS, Krishnan S, Delclos ME, et al. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol 2014; 37: 461-6. doi: 10.1097/COC.0b013e31827e52a3
- Jokic V, Savic-Vujovic K, Spasic J, Stanic N, Marinkovic M, Radosavljevic D, et al. Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity. Expert Rev Anticancer Ther 2021; 6: 673-9. doi: 10.1080/14737140.2021.1893694
- Shibutani M, Maeda K, Nagahara H, Noda E, Ohtani H, Nishiguchi Y, et al. A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer. Anticancer Res 2013; 33: 3291-4. PMID: 23898094
- Zhang J, Zhang HY, Li J, Shao XY, Zhang CX. The elevated NLR, PLR and PLT may predict the prognosis of patients with colorectal cancer: a systematic review and meta-analysis. Oncotarget 2017; 8: 68837-46. doi: 10.18632/oncotarget.18575
- Tanić M, Krivokuća A, Čavić M, Mladenović J, Plesinac Karapandžić V, Beck S, et al. Molecular signature of response to preoperative radiotherapy in locally advanced breast cancer. Radiat Oncol 2018; 13: 193. doi: 10.1186/s13014-018-1129-4
- Bergom C, West CM, Higginson DS, Abazeed ME, Arun B, Bentzen SM, et al. The Implications of genetic testing on radiation therapy decisions: a guide for radiation oncologists. Int J Radiat Oncol Biol Phys 2019; 105: 698-712. doi: 10.1016/j.ijrobp.2019.07.026